Symberix, an early-stage spin-out of the University of North Carolina at Chapel Hill, aims to improve human health by pioneering the development of symbiotic drugs that work by controlling bacteria without killing them. Symberix’s scientific founder, Matthew Redinbo, PhD, was the first to demonstrate the feasibility of therapeutically controlling the mammalian microbiome with small-molecule symbiotic drugs. Based on this breakthrough research, the company is advancing a first-in-class approach to improve the treatment of serious lower gastrointestinal (GI) diseases as well as mitigate the debilitating lower GI side effects associated with various cancer, pain and immunosuppressive therapies. Our vision: Safe and effective pharmaceutical control of the microbiome.